pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,491
stories
11d
Recon: FDA approves drugs for Parkinson’s, bile duct cancer, rare soft tissue disease; Merck, Daiichi scrap application for ADC ...
raps
13d
How NIH’s Nicole Kleinstreuer is working to reduce animal testing while avoiding a ‘backlash’
fiercebiotech
13d
Endpoints 11 2026 winner Stipple Bio is taking precision to the next level
endpoints
13d
Endpoints 11 2026 winner Medici believes the future of cancer therapy is personalized
endpoints
13d
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
13d
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
13d
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
biospace
13d
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
13d
Merck expands Welireg's use to broader set of kidney cancer patients
endpoints
13d
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
biospace
14d
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
14d
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
14d
Grail multicancer detection test wins FDA advisers’ backing
biopharma dive
14d
The FDA’s Overton era, and dispatches from Shanghai
stat
14d
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
biospace
14d
Elevar wins first FDA approval with second-line drug for bile duct cancer
endpoints
14d
Senate finance committee backs Chris Klomp, advancing him to full Senate vote
stat
14d
Merck reveals study success, and possible safety worries, for eye drug hopeful
biopharma dive
14d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
14d
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
14d
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
14d
Merck’s return to ophthalmology snags first success
endpoints
14d
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
biospace
14d
One of the most contagious diseases on the planet is having its worst U.S. outbreak since 1991
stat
15d
STAT+: Why Gilead can’t stop talking about its ambitions in immunology
stat
15d
How radioligand therapy is rewriting cancer care
biospace
15d
China’s Henlius carves out $440M T-cell engager deal with Amberstone
fiercebiotech
15d
Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution
stat
15d
Opinion: Measles almost killed me. Now I’m a doctor — and I’m scared of what’s happening
stat
15d
STAT+: Trump boast on drug pricing policy overstated state-level interest in federal program
stat
← prev
page 5 of 50
next →
